CPRX Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of 13.07%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Corcept Therapeutics's return on equity of 21.3%.

Catalyst Pharmaceuticals has a consensus price target of $34.00, signalling upside risk potential of 45.49%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 96.85%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.697, which suggesting that the stock is 30.252% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Corcept Therapeutics's net income of $20.5M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.89x while Corcept Therapeutics's PE ratio is 60.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.50x versus 11.89x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -111.65%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Catalyst Pharmaceuticals has a consensus price target of $34.00, signalling upside risk potential of 45.49%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.54 which suggests that it could grow by 78.37%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.697, which suggesting that the stock is 30.252% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.865%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Ionis Pharmaceuticals quarterly revenues of $131.6M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.89x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.50x versus 6.87x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of 24.89%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Nektar Therapeutics's return on equity of -133.07%.

Catalyst Pharmaceuticals has a consensus price target of $34.00, signalling upside risk potential of 45.49%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 735.17%. Given that Nektar Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.697, which suggesting that the stock is 30.252% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.715%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Nektar Therapeutics's net income of $7.3M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.89x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.50x versus 1.23x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -147.92%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Xencor's return on equity of -32.34%.

Catalyst Pharmaceuticals has a consensus price target of $34.00, signalling upside risk potential of 45.49%. On the other hand Xencor has an analysts' consensus of $28.20 which suggests that it could grow by 238.54%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.697, which suggesting that the stock is 30.252% less volatile than S&P 500. In comparison Xencor has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.85%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Xencor quarterly revenues of $32.7M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Xencor's net income of -$48.4M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.89x while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.50x versus 4.46x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.